Contact
searchSearch
HMP Global
Login

Ovarian Cancer Specialty Channel

Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
Conference Coverage
Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results,...
06/13/2024
Oncology
Conference Coverage
Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES...
06/13/2024
Oncology
Conference Coverage
Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer
06/03/2024
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology
News
Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype
02/09/2024
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23...
02/09/2024
Oncology
Quiz
Front-Line Treatment Options for Ovarian Cancer
12/20/2023
12/20/2023
Oncology
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
Bradley Monk, MD
Conference Coverage
Front-Line Treatment Options for Ovarian Cancer
12/07/2023
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates...
12/07/2023
Oncology
Quiz
New and Emerging Targeted Therapies for Relapsing Ovarian Cancer
11/29/2023
11/29/2023
Oncology

News

Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
Conference Coverage
Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results,...
06/13/2024
Oncology
Conference Coverage
Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES...
06/13/2024
Oncology
Conference Coverage
Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer
06/03/2024
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology
News
Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype
02/09/2024
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23...
02/09/2024
Oncology
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
Bradley Monk, MD
Conference Coverage
Front-Line Treatment Options for Ovarian Cancer
12/07/2023
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates...
12/07/2023
Oncology
News
Ofranergene Obadenovec Plus Paclitaxel Did Not Improve Survival Outcomes Among Patients With Recurrent, Platinum-Resistant Ovarian Cancer
11/13/2023
According to results from the phase 3 OVAL/GOG 3018 study, the addition of ofranergene obadenovec to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) among patients with recurrent platinum-resistant ovarian...
According to results from the phase 3 OVAL/GOG 3018 study, the addition of ofranergene obadenovec to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) among patients with recurrent platinum-resistant ovarian...
According to results from the...
11/13/2023
Oncology

Interactive Features

Quiz
Front-Line Treatment Options for Ovarian Cancer
12/20/2023
12/20/2023
Oncology
Quiz
New and Emerging Targeted Therapies for Relapsing Ovarian Cancer
11/29/2023
11/29/2023
Oncology
Quiz
Maintenance Olaparib Rechallenge for Ovarian Cancer
10/31/2023
10/31/2023
Oncology
Quiz
Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer
05/16/2023
How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?
How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?
How is Sleeping Beauty...
05/16/2023
Oncology
Quiz
Quiz: FDA Approves Mirvetuximab Soravtansine
12/15/2022
What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?
What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?
What treatment must patients...
12/15/2022
Oncology
Quiz
Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice
12/02/2022
What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?
What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?
What is the most prevalent...
12/02/2022
Oncology
Quiz
Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer
11/03/2022
A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?
A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?
A phase 3 open-label study found...
11/03/2022
Oncology
Quiz
Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer
03/27/2022
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at...
03/27/2022
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology

Recent News

Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
News
Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype
02/09/2024
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23...
02/09/2024
Oncology
News
Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer
12/19/2023
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology
News
Ofranergene Obadenovec Plus Paclitaxel Did Not Improve Survival Outcomes Among Patients With Recurrent, Platinum-Resistant Ovarian Cancer
11/13/2023
According to results from the phase 3 OVAL/GOG 3018 study, the addition of ofranergene obadenovec to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) among patients with recurrent platinum-resistant ovarian...
According to results from the phase 3 OVAL/GOG 3018 study, the addition of ofranergene obadenovec to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) among patients with recurrent platinum-resistant ovarian...
According to results from the...
11/13/2023
Oncology
Conference Coverage
Addition of Atezolizumab to Chemotherapy and Maintenance Niraparib Did Not Improve PFS or ORR in Late-Relapsing, Recurrent Ovarian Cancer
11/03/2023
According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...
According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...
According to primary analysis...
11/03/2023
Oncology
Conference Coverage
Standard of Care Superior to Olaparib With or Without Cediranib Among Patients With Relapsed, Platinum-Sensitive Ovarian Cancer
10/26/2023
According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.
According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.
According to data from the phase...
10/26/2023
Oncology
Conference Coverage
Maintenance Senaparib Improved PFS Among Patients With Newly Diagnosed, Advanced Ovarian Cancer
10/25/2023
According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...
According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...
According to results from the...
10/25/2023
Oncology
News
Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Significantly Improved Long-Term Survival Outcomes in Advanced Ovarian Cancer
10/12/2023
According to updated survival results from the phase 3 OVHIPEC-1 trial, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery significantly improved long-term progression-free survival and overall...
According to updated survival results from the phase 3 OVHIPEC-1 trial, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery significantly improved long-term progression-free survival and overall...
According to updated survival...
10/12/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use